Loading…
← CockpitCompetitor Analysis › 603538.SS Ningbo Menovo Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Ningbo Menovo Pharmaceutical Co., Ltd. Class A603538.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Ningbo-based API and CDMO manufacturer exporting active pharmaceutical ingredients to generic drugmakers abroad.

≈ A small Chinese API/CDMO exporterMomentum laggard 6
Mkt cap
$945M
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$77.5M
20-day average traded
Fwd P/E
42.3×
forward earnings
ROIC−WACC
-0.2 pp
WACC 5.0%
Hurdle
+7 pp
Req g minus delivered
Next earnings
155 days
22 Apr 2027
Close · CNYCN¥18.98
1D-0.8%
1W-13.5%
1M-14.5%
3M-41.7%
6M-47.7%
YTD+38.1%
1Y+15.6%
ATR %6.4%
52w lowhigh62.2% off high

What Ningbo Menovo Pharmaceutical does

Ningbo-based API and CDMO manufacturer exporting active pharmaceutical ingredients to generic drugmakers abroad.

In one line: A small Chinese API/CDMO exporter.

Products and services

  • Active pharmaceutical ingredients
  • CDMO contract manufacturing

Customers

  • Overseas generic-drug makers

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients
  • API manufacturing and CDMO

What could go right

  • Export demand for API/CDMO capacity

What could go wrong

  • FX and export price competition

Moat: none (scale). Commodity API/CDMO producer competing mainly on cost and regulatory filings.

Headquarters: Ningbo, China · Employees: 2,370

Named competitors

Ningbo Menovo Pharmaceutical at a glance

Size Ningbo Menovo Pharmaceutical (603538.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $945M, the 2259th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.98 on 18 Nov 2026.

Performance Over six months the shares fell 47.7%, against -18.4% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 18.6% over the last twelve months (peer median -4.4%); the operating margin is 8.8% (peer median 12.2%).

Valuation It trades at 42.3× forward earnings against a peer median of 22.9× (3rd most expensive of 10).

Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.2 points below its cost of capital (5.0% WACC).

Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 83603538.SS 53
Six months, rebased to 100: Ningbo Menovo Pharmaceutical against the median of its 20 peers (local-currency closes).

Ningbo Menovo Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.83BCN¥1.50BCN¥1.37BCN¥1.21BCN¥1.45B
Revenue growth—+10%+13%-16%—
Gross profitCN¥607MCN¥489MCN¥408MCN¥334MCN¥533M
EBITDAn/aCN¥278MCN¥221MCN¥146MCN¥313M
Net incomeCN¥110MCN¥102MCN¥66.8MCN¥11.6MCN¥339M
Free cash flowCN¥76.4MCN¥60.3M-CN¥77.4M-CN¥202M-CN¥288M
Capital expenditureCN¥149MCN¥112MCN¥179MCN¥220MCN¥572M
Total debtCN¥1.08BCN¥1.76BCN¥1.65BCN¥1.52BCN¥1.43B

Quarterly statements and history in the cockpit →

Ningbo Menovo Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%STAR20050024376004223002946887596881770392001795MLTX4565IMTXPGHL2595SPTX688382AARTIPHARM603538.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Ningbo Menovo Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%20×40×60×STAR200530029403920017954565600129603538.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ningbo Menovo Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%STAR200500243760025203920030040117954565688382603538.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ningbo Menovo Pharmaceutical is the large dot.

Ningbo Menovo Pharmaceutical competitors and peer comparison

Head to head with its named competitors (603538.SS vs 600521.SS vs 600267.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ningbo Menovo Pharmaceutical 603538.SS$945M-48%+19%9%42.3×11.6%
Zhejiang Huahai Pharmaceutical 600521.SS$3.61B0%+10%12%20.1×6.4%
Zhejiang Hisun Pharmaceutical 600267.SS$2.19B+14%-7%15%15.0×-9.7%

How Ningbo Menovo Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ningbo Menovo Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603538.SSPeer medianRank in peer set
1-month return-14.5%-8.3%7th lowest of 21
6-month return-47.7%-18.4%2nd lowest of 21
Distance from 52-week high-62.2%-44.2%5th lowest of 21
Revenue growth (TTM)+18.6%-4.4%5th highest of 18
Operating margin8.8%12.2%9th lowest of 18
Forward P/E42.3×22.9×3rd most expensive of 10
Growth the price implies (Req g, 7 yrs)11.6%7.1%3rd most demanding of 11
Growth delivered (Del g)+4.9%+8.5%5th lowest of 11
Hurdle (Req g minus delivered)+6.7 pp-0.5 pp5th most demanding of 11
ROIC minus cost of capital-0.2 pp-2.0 pp6th highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%42.3×11.6%+4.9%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%15.9×17.6%+7.8%
SSY 2005.HKHong Kong$948M+8%-4%12%12.5×2.3%-0.5%
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%n/a7.7%-6.9%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%n/an/an/a
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%n/a10.3%-13.7%
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%n/an/an/a
Oscotec 039200.KSSouth Korea$923M-32%+510%59%50.2×-10.2%+18.1%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%22.9×9.1%+13.4%
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%9.8×-3.7%+13.8%
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Immatics IMTXUnited States$913M-46%-44%-589%n/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%n/an/an/a
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a

Questions

Who are Ningbo Menovo Pharmaceutical's main competitors?
Named competitors: Zhejiang Huahai Pharmaceutical (600521.SS), Hisun Pharmaceutical (600267.SS). The cockpit's measured peer set (industry) also includes Strides Pharma Science (STAR.NS), SSY (2005.HK), Harbin Gloria Pharmaceuticals (002437.SZ), KPC Pharmaceuticals (600422.SS), Guangxi Wuzhou Zhongheng (600252.SS), China Resources Boya Bio-pharmaceutical (300294.SZ).
Is Ningbo Menovo Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 42.3× against a peer median of 22.9×, 3rd most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Ningbo Menovo Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -47.7% against -18.4% for the median peer; over one year +15.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.